These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 32096613)

  • 1. A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy.
    Karaa A; Haas R; Goldstein A; Vockley J; Cohen BH
    J Cachexia Sarcopenia Muscle; 2020 Aug; 11(4):909-918. PubMed ID: 32096613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial.
    Karaa A; Bertini E; Carelli V; Cohen BH; Enns GM; Falk MJ; Goldstein A; Gorman GS; Haas R; Hirano M; Klopstock T; Koenig MK; Kornblum C; Lamperti C; Lehman A; Longo N; Molnar MJ; Parikh S; Phan H; Pitceathly RDS; Saneto R; Scaglia F; Servidei S; Tarnopolsky M; Toscano A; Van Hove JLK; Vissing J; Vockley J; Finman JS; Brown DA; Shiffer JA; Mancuso M;
    Neurology; 2023 Jul; 101(3):e238-e252. PubMed ID: 37268435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy.
    Karaa A; Haas R; Goldstein A; Vockley J; Weaver WD; Cohen BH
    Neurology; 2018 Apr; 90(14):e1212-e1221. PubMed ID: 29500292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.
    Thompson WR; Manuel R; Abbruscato A; Carr J; Campbell J; Hornby B; Vaz FM; Vernon HJ
    Genet Med; 2024 Jul; 26(7):101138. PubMed ID: 38602181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism.
    Reid Thompson W; Hornby B; Manuel R; Bradley E; Laux J; Carr J; Vernon HJ
    Genet Med; 2021 Mar; 23(3):471-478. PubMed ID: 33077895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in primary mitochondrial myopathies.
    de Barcelos IP; Emmanuele V; Hirano M
    Curr Opin Neurol; 2019 Oct; 32(5):715-721. PubMed ID: 31408013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psychometric performance of the Primary Mitochondrial Myopathy Symptom Assessment (PMMSA) in a randomized, double-blind, placebo-controlled crossover study in subjects with mitochondrial disease.
    Gwaltney C; Stokes J; Aiudi A; Mazar I; Ollis S; Love E; Karaa A; Houts CR; Wirth RJ; Shields AL
    J Patient Rep Outcomes; 2022 Dec; 6(1):129. PubMed ID: 36562873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No effect of resveratrol in patients with mitochondrial myopathy: A cross-over randomized controlled trial.
    Løkken N; Khawajazada T; Storgaard JH; Raaschou-Pedersen D; Christensen ME; Hornsyld TM; Krag T; Ørngreen MC; Vissing J
    J Inherit Metab Dis; 2021 Sep; 44(5):1186-1198. PubMed ID: 33934389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of omaveloxolone in patients with mitochondrial myopathy: MOTOR trial.
    Madsen KL; Buch AE; Cohen BH; Falk MJ; Goldsberry A; Goldstein A; Karaa A; Koenig MK; Muraresku CC; Meyer C; O'Grady M; Scaglia F; Shieh PB; Vockley J; Zolkipli-Cunningham Z; Haller RG; Vissing J
    Neurology; 2020 Feb; 94(7):e687-e698. PubMed ID: 31896620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acipimox in Mitochondrial Myopathy (AIMM): study protocol for a randomised, double-blinded, placebo-controlled, adaptive design trial of the efficacy of acipimox in adult patients with mitochondrial myopathy.
    ; Abouhajar A; Alcock L; Bigirumurame T; Bradley P; Brown L; Campbell I; Del Din S; Faitg J; Falkous G; Gorman GS; Lakey R; McFarland R; Newman J; Rochester L; Ryan V; Smith H; Steel A; Stefanetti RJ; Su H; Taylor RW; Thomas NJP; Tuppen H; Vincent AE; Warren C; Watson G
    Trials; 2022 Sep; 23(1):789. PubMed ID: 36127727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural history comparison study to assess the efficacy of elamipretide in patients with Barth syndrome.
    Hornby B; Thompson WR; Almuqbil M; Manuel R; Abbruscato A; Carr J; Vernon HJ
    Orphanet J Rare Dis; 2022 Sep; 17(1):336. PubMed ID: 36056411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elamipretide Topical Ophthalmic Solution for the Treatment of Subjects with Leber Hereditary Optic Neuropathy: A Randomized Trial.
    Karanjia R; Sadun AA
    Ophthalmology; 2024 Apr; 131(4):422-433. PubMed ID: 37923251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
    Loncharich MF; Anderson CW
    ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identifying responders to elamipretide in Barth syndrome: Hierarchical clustering for time series data.
    Van den Eynde J; Chinni B; Vernon H; Thompson WR; Hornby B; Kutty S; Manlhiot C
    Orphanet J Rare Dis; 2023 Apr; 18(1):76. PubMed ID: 37041653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of AMG 714 in adults with coeliac disease exposed to gluten challenge: a phase 2a, randomised, double-blind, placebo-controlled study.
    Lähdeaho ML; Scheinin M; Vuotikka P; Taavela J; Popp A; Laukkarinen J; Koffert J; Koivurova OP; Pesu M; Kivelä L; Lovró Z; Keisala J; Isola J; Parnes JR; Leon F; Mäki M
    Lancet Gastroenterol Hepatol; 2019 Dec; 4(12):948-959. PubMed ID: 31494096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epitope-specific immunotherapy targeting CD4-positive T cells in coeliac disease: two randomised, double-blind, placebo-controlled phase 1 studies.
    Goel G; King T; Daveson AJ; Andrews JM; Krishnarajah J; Krause R; Brown GJE; Fogel R; Barish CF; Epstein R; Kinney TP; Miner PB; Tye-Din JA; Girardin A; Taavela J; Popp A; Sidney J; Mäki M; Goldstein KE; Griffin PH; Wang S; Dzuris JL; Williams LJ; Sette A; Xavier RJ; Sollid LM; Jabri B; Anderson RP
    Lancet Gastroenterol Hepatol; 2017 Jul; 2(7):479-493. PubMed ID: 28506538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide.
    Daubert MA; Yow E; Dunn G; Marchev S; Barnhart H; Douglas PS; O'Connor C; Goldstein S; Udelson JE; Sabbah HN
    Circ Heart Fail; 2017 Dec; 10(12):. PubMed ID: 29217757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.